A Post Authorization Registry Study of Participants Treated With LEQEMBI

计划入组 400 人 · 首次发布于 2026 年 8 月 13 日

A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

计划入组 3,000 人 · 首次发布于 2025 年 2 月 6 日

A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)

计划入组 400 人 · 首次发布于 2026 年 8 月 24 日

Lecanemab(Leqembi)

Rx

FDA Approves Weekly Autoinjector for Eisai's Alzheimer's Drug Leqembi, Enabling At-Home Treatment

Novo Nordisk's Semaglutide Fails in Alzheimer's Trials, Boosting Biogen's Leqembi Prospects

LEQEMBI Shows Measurable Target Engagement with Alzheimer's Protofibrils in Cerebrospinal Fluid